Kairos Pharma Files 8-K on Leadership Changes & Financials
Ticker: KAPA · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1962011
Sentiment: neutral
Topics: leadership-change, corporate-governance, financials
TL;DR
Kairos Pharma 8-K: New execs, board changes, and financials filed. Dec 10th event date.
AI Summary
Kairos Pharma, LTD. filed an 8-K on December 13, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported being December 10, 2024.
Why It Matters
This filing indicates significant changes in Kairos Pharma's leadership and corporate governance, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in leadership and the filing of financial statements can signal shifts in company strategy or performance, warranting closer investor attention.
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- December 10, 2024 (date) — Earliest event reported
- December 13, 2024 (date) — Filing date
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
FAQ
What specific officer positions were affected by the appointments mentioned in the filing?
The filing indicates the appointment of certain officers, but does not specify which particular positions were filled or changed in this summary.
Were there any specific reasons cited for the departure of directors?
The filing notes the departure of directors but does not provide specific reasons for their departure in the provided text.
What type of financial statements were included with this 8-K filing?
The filing states that financial statements and exhibits are included, but does not detail the specific types of statements (e.g., balance sheet, income statement) in this summary.
What is the primary business of Kairos Pharma, LTD.?
Kairos Pharma, LTD. operates in the Pharmaceutical Preparations industry, SIC code 2834.
When is Kairos Pharma, LTD.'s fiscal year end?
Kairos Pharma, LTD.'s fiscal year ends on December 31st.
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 10 · Accepted 2024-12-13 16:10:25
Key Financial Figures
- $0 — ch registered Common Stock, par value $0.001, per share KAPA NYSE American
- $50,000 — titled to receive an annual cash fee of $50,000, payable in equal quarterly installment
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex10-1.htm (EX-10.1) — 40KB
- 0001493152-24-049994.txt ( ) — 265KB
- kapa-20241210.xsd (EX-101.SCH) — 3KB
- kapa-20241210_lab.xml (EX-101.LAB) — 33KB
- kapa-20241210_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Kairos Pharma, Ltd. (Exact name of registrant as specified in its charter) Delaware 001-42275 46-2993314 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (Address of principal executive offices) (Zip Code) (310) 948-2356 Registrant's telephone number, including area code N/A (Former name or former address, if changed from last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name of each exchange on which registered Common Stock, par value $0.001, per share KAPA NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On December 10, 2024, Dr. Rosemary Mazanet resigned from her position as a member of the board of directors (the "Board") of Kairos Pharma, Ltd. (the "Company"), with such resignation to be effective upon the Company's appointment of a new independent director to fill her role. Dr. Mazanet's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices but rather was due to personal reasons. The Company thanks Dr. Mazanet for her service as a member of the Board and wishes her great success going forward. Appointment of Director On December 10, 2024, the Board appointed Dr. Rahul Singhvi to serve as a director of the Board, effective immediately. Dr. Singhvi will also serve as a member of the Board's audit committee and chair of the Board's compensation committee and nominating and corporate governance committee. Dr. Singhvi, age 59, is a global leader in the Life Sciences industry and is cofounder of the U.S.-based biomanufacturing company, Resilience (National Resilience, Inc.). Prior to cofounding Resilience in 2020, Dr. Singhvi was an Operating Partner at Flagship Pioneering, where he founded and operated companies launched from Flagship's innovation foundry, Flagship Venture Labs. Before joining Flagship, he was the Chief Operating Officer of Takeda's Vaccine Business Unit where he led worldwide vaccine manufacturing operations. Before Takeda, Dr. Singhvi was President and CEO of Novavax, Inc. (Nasdaq:NVAX) where he led the company's transformation into a global vaccine player. Dr. Singhvi's career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing. Dr. Singhvi serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis (Nasdaq:CDXS) and for Garuda Therapeutics (private). Dr. Singhvi graduated as the top ranked chemical engineer from the Indian Institute of Technology, Kanpur, India and obtained both his M.S. and Sc.D. degrees in chemical engineering from MIT. He received an MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar. Because of Dr. Singhvi's experience and knowledge in the operation and leadership of early-stage public healthcare companies, we believe he will be able to provide valuable insights and contributions to our Board. In conjunction with his appointment, the Company entered into a director offer letter (the "Director Offer Letter") with Dr. Singhvi. Pursuant to the terms of the Director Offer Letter, Dr. Singhvi is entitled to receive an annual cash fee of $50,000, payable in equal quarterly installments, and is also entitled to a grant of $50,000 in restricted stock units ("RSUs"